Dr Mymoona Alzouebi

Consultant Clinical Oncologist

MBChB, MRCP, DTMH, MSc Oncology, FRCR

Personal profile

Dr Alzouebi is Consultant Clinical Oncologist specialising in the treatment of cancers of the urinary tract. Her areas of interest are in the treatment of prostate, kidney and bladder cancer with systemic anti-cancer chemotherapy, immunotherapy and radiotherapy.

She is an expert in cancer care using the most advanced and up to date treatment modalities.

She is actively involved in clinical trials and research and is the local principal investigator on several national clinical trials.

Dr Alzouebi holds a substantive NHS post as a Consultant Clinical Oncologist, Weston Park Hospital; Sheffield Teaching Hospital NHS Foundation Trust.

Dr Alzouebi qualified from the University of Sheffield in 2004. She undertook general medical training in the Yorkshire Deanery and achieved MRCP and DTMH qualifications.

She completed the Clinical Oncology Training Programme at Weston Park Hospital in Sheffield. She obtained a Distinction in a Master’s Degree in Oncology from the University of Nottingham and her dissertation research was published in a peer reviewed journal.

She successfully obtained Fellow of Royal College of Radiologist (Clinical Oncology) qualification in 2012.

Treatments Offered

  • Systemic Drug therapy/Chemotherapy: Novel Targeted Anticancer Drug Treatment; Systemic Chemotherapy; Immunotherapy; Monoclonal Antibodies; Endocrine therapy; Radium-223; Tyrosine Kinase therapy
  • Radiotherapy; Intensity Modulated Radiotherapy (IMRT); Image Guided Radiotherapy (IGRT), Adaptive Radiotherapy Stereotactic Ablative Radiotherapy; SABR
  • In partnership with Genesiscare; SpaceOAR for prostate radiotherapy
  • Areas of interest
  • Advanced radiotherapy techniques for prostate and bladder cancer
  • Prostate SABR
  • Chemotherapy in prostate, kidney and bladder cancer

Research Publications

•M Alzouebi, R Jones. Outcomes of 10 years prescribing practice for first line metastatic kidney cancer. NCRI 2018

•M Alzouebi, JR Goepel, JM Horsman and BW Hancock. Primary thyroid lymphoma: The 40-year experience of a UK lymphoma treatment centre. Int J Oncol 40: 2075-2080, 2012

•M Alzouebi, S Pledge and J Martin. Are outcomes of adjuvant vaginal vault brachytherapy in endometrial cancer related to the way it is delivered? Journal of Radiotherapy in Practice. FirstView Article : pp 1-14 Published online: 12 December 2011

•M Alzouebi, P Fisher, PJ Woll, MQ Hatton, BH Foran. Audit of adjuvant vinorelbine and cisplatin for patients with resected NSCLC. Lung Cancer 2010;67:S1

•M Alzouebi, P Sarrigiannis, M Hadjivassiolou. Acute Polyradiculopathy with renal failure; mind the anion gap – Journal of Neurology, Neurophysiology and Psychiatry Psychiatry 2008;79:842-844

•M Alzouebi. Paediatric Chest Radiographs. StudentBMJ 2005; 13:309-352

•M Alzouebi, M McAlindon, DS Sanders. Patients starving before percutaneous endoscopic gastrostomy (PEG) placement may be at risk of refeeding syndrome. BAPEN 2004; 63 (1)

Professional Memberships

  • General Medical Council
  • Royal College of Radiologists
  • British Uro-Oncology Group

Clinical Interests

Radiotherapy; Chemotherapy; Biological Treatment, Novel Targeted Anticancer Drug Treatment; Intensity Modulated Radiotherapy (IMRT); Prostate Cancer; Bladder Cancer; Kidney Cancer; IMRT, IGRT, Adaptive Radiotherapy; Systemic Chemotherapy; Immunotherapy; Monoclonal Antibodies; Biological Therapy; Endocrine Oncology; Urological Cancers; Stereotactic Ablative Radiotherapy; SABR; Radium-223. 

Current NHS and /or University Posts

Consultant in Clinical Oncology in Urological Malignancies at Weston Park Cancer Centre, Sheffield

Research Interests

M Alzouebi, R Jones. Outcomes of 10 years prescribing practice for first line metastatic kidney cancer. NCRI 2018.

M Alzouebi, JR Goepel, JM Horsman and BW Hancock. Primary

Useful Links

Request an appointment

Please complete the form below, making sure you provide us with as much detail as possible. We aim to answer all enquiries within 24 hours, but due to high volume we sometimes might not be able to do so

*Required field.

Title *
First Name *
Last Name *
Email Address *
Daytime tel *
Postcode *
Consultant
Hospital *
Treatment
Type of enquiry
How would you prefer to fund your treatment? *
Please use this box to tell us more about your enquiry
(Max 500 characters)

500 Characters remaining

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.